DealLawyers.com Blog

May 20, 2014

Allergan Continues to Break the Mold: Nonbinding Shareholder Vote Before Vote

As I blogged last month, William Ackman’s Pershing Square Capital has teamed up with Valeant to make a hostile bid for Allergan as part of a new paradigm of a hedgie and corporate teaming up. Allergan has formally rejected any overtures so far.

Last week, Pershing Square Capital filed this preliminary proxy statement so that Allergan shareholders could attend a “meeting” of sorts (in person or by proxy) solely to cast a non-binding vote on whether Allergan should negotiate with Valeant on a deal. This straw poll is another novelty of this deal. Here’s some articles about this tactic:

Reuter’s “No downside in Allergan ‘meeting'”
The Activist Investor’s “A Shareholder ‘Get Together'”
WSJ’s “Pershing Square Wants Allergan Holders to Push for Merger Talks”

Take Me Back to the Main Blog Page

Blog Preferences: Subscribe, unsubscribe, or change the frequency of email notifications for this blog.

UPDATE EMAIL PREFERENCES

Try Out The Full Member Experience: Not a member of CompensationStandards.com? Start a free trial to explore the benefits of membership.

START MY FREE TRIAL